Söndag 22 December | 08:16:14 Europe / Stockholm

Kalender

Tid*
2024-12-20 - Kvartalsrapport 2024-Q3
2024-12-16 - 15-6 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-08-14 - Extra Bolagsstämma 2024
2024-05-29 - X-dag ordinarie utdelning CIRCA 0.00 NOK
2024-05-28 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning CIRCA 0.00 NOK
2023-05-25 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning CIRCA 0.00 NOK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-02 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-06-17 - X-dag ordinarie utdelning CIRCA 0.00 NOK
2021-06-16 - Årsstämma
2021-05-27 - Kvartalsrapport 2021-Q1
2021-03-02 - Bokslutskommuniké 2020

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Circa Group är verksamma inom bioteknik. Bolaget är en utvecklare av biokemikalier som vidare används för omvandling av avfallsmassa till diverse biokemiskt material. Tekniken används inom energisektorn vid olika produktionsprocesser. Bolaget grundades under 2006 och innehar störst verksamhet runtom den europeiska marknaden. Circa Group har sitt huvudkontor i Oslo, Norge.
2023-07-06 08:00:00
OSLO, NORWAY - 6 July 2023 - Circa Group AS (stock symbol: CIRCA) has applied
for patents for two new solvents for CO2 capture processes.

As both the interest and the urgency to capture and transform carbon dioxide
(CO2) emissions increases, Circa has developed two new CO2 solvents from its
platform molecule, levoglucosenone (LGO).

The two new solvents named Furatech:1 and Furatech:2 are the product of 12
months of development and testing across a range of new LGO-based molecules
within Circa's R&D team.

The Furatech products have been designed to be used in several current CO2
capture processes and discussions are underway about further optimisation with
our engineering partners.

"Applying for patents is a major step and we are sufficiently excited about the
performance of these two new CO2 solvents that getting protection in place as
quickly as possible is a priority," says Tony Duncan, Circa CEO. "Furatech
testing has shown good CO2 capture performance across multiple cycles, as well
as lower energy requirements in the desorption phase compared to current
industry standards."

With the ReSolute plant commissioning planned for mid-2024, further testing and
trialling of Furatech:1 and Furatech:2 will continue in parallel.



About Circa
Established in 2006, Circa Group converts sustainable biomass into advanced
bio-based chemicals with its proprietary FuracellTM process. Its developing
levoglucosenone based product portfolio includes bio-polymers and bio-solvents
including CyreneTM. By creating renewable chemicals from cellulose, Circa is
extracting value from non-food, biomass and addressing a gap in the market by
providing bio-based alternatives contributing to a lower carbon and more
circular economy.
https://circa-group.com


Investor Contact Media Contact
Tone Leivestad Kathryn Sheridan
Chief Financial Officer Sustainability Consult
Circa Group AS ks@sustainabilityconsult.com
tone.leivestad@circa-group.com